Cancer Research Targets Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bevaart, L.
Right arrow Articles by Leusen, J. H.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bevaart, L.
Right arrow Articles by Leusen, J. H.W.
[Cancer Research 66, 1261-1264, February 1, 2006]
© 2006 American Association for Cancer Research

Priority Reports

The High-Affinity IgG Receptor, Fc{gamma}RI, Plays a Central Role in Antibody Therapy of Experimental Melanoma

Lisette Bevaart1, Marco J.H. Jansen1, Martine J. van Vugt2, J. Sjef Verbeek3, Jan G.J. van de Winkel1,2 and Jeanette H.W. Leusen1

1 Immunotherapy Laboratory, Department of Immunology, University Medical Center Utrecht; 2 Genmab, Utrecht, the Netherlands; and 3 Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands

Requests for reprints: Jan G.J. van de Winkel, Immunotherapy Laboratory, Department of Immunology, University Medical Center Utrecht, Lundlaan 6, KC.02.085.2, 3584 EA Utrecht, the Netherlands. Phone: 31-30-212-3100; Fax: 31-30-212-111; E-mail: j.vandewinkel{at}azu.nl.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
We examined the role of Fc{gamma}R in antibody therapy of metastatic melanoma in wild-type and different Fc{gamma}R knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual Fc{gamma}R knock-out mice revealed the high-affinity IgG receptor, Fc{gamma}RI (CD64), to represent the central Fc{gamma}R for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of Fc{gamma}RI. (Cancer Res 2006; 66(3): 1261-4)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Antibodies represent promising therapeutic candidates due to their high specificity and low toxicity profiles. The exact variables and mechanisms contributing to the therapeutic potential of anticancer antibodies remain unclear. Antibodies can initiate various effects, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement dependent cytotoxicity, and induction of apoptosis (1). A better understanding of the working mechanisms of therapeutic antibodies is essential to further enhance the efficacy of antibody therapy. In this study, we address the role of IgG receptors (Fc{gamma}R) in antibody-induced antitumor activity. Four classes of murine leukocyte Fc{gamma}R are currently distinguished [Fc{gamma}RI (CD64), Fc{gamma}RII (CD32), Fc{gamma}RIII (CD16), and the recently described Fc{gamma}RIV], which differ in cell distribution and function. Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV are activatory receptors, whereas Fc{gamma}RII can mediate inhibitory effects (2, 3). The B16F10 lung metastasis model represents a validated model to study antibody therapy using TA99, a mouse IgG2a antibody recognizing the gp75 tumor antigen (4). Treatment of wild-type mice with TA99 after tumor challenge has been shown to markedly reduce numbers of lung metastases (5). A role for Fc{gamma}R in TA99 antibody-mediated effects has been documented with the use of FcR {gamma}-chain knock-out mice, which lack all activatory leukocyte Fc{gamma}R (6, 7). The relative contribution of individual Fc{gamma}R classes, however, has not been previously assessed. Antibody therapy is often combined with other treatment regimens, such as antiangiogenic or cytostatic drugs, to further enhance therapeutic efficacy. Agonists of Toll-like receptors (TLR) can effectively boost antibody-induced effects (8). Monophosphoryl lipid A (MPL), a TLR-4 agonist, is a chemically modified lipopolysaccharide (LPS) derived from Salmonella minnesota (9). As adjuvant effects of MPL in vivo have been documented (10, 11), we tested the influence of MPL on the outcome of treatment when administered in combination with TA99 antibody. In this report, we observed Fc{gamma}RI to be essential for TA99 antibody-induced antitumor effects in C57Bl/6 mice. MPL further enhanced TA99-mediated antitumor effects.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Mice. C57Bl/6 wild-type mice were obtained from Janvier (Le Genest Saint Isle, France). Fc{gamma}RI (CD64) knock-out mice (12), Fc{gamma}RIII (CD16) knock-out mice (13), and FcR {gamma}-chain knock-out mice (7), all in the C57Bl/6 background, were bred and maintained in the Central Animal Laboratory, Utrecht University. Experiments were done with 7- to 12-week-old mice and were all approved by the Utrecht University animal ethics committee.

Cell lines and TA99 antibody. The B16F10 mouse melanoma cell line was obtained from the National Cancer Institute (Frederick, MD). Cells were cultured in RPMI 1640 (Life Technologies, Paisley, United Kingdom) supplemented with 10% fetal bovine serum (Integro, Dieren, the Netherlands), 50 units/mL penicillin (Life Technologies), and 50 µg/mL streptomycin (Life Technologies). Hybridoma HB-8704 (American Type Culture Collection, Manassas, VA), which produces TA99 antibody, was cultured under serum-free conditions with HyQ ADCF-monoclonal antibody (mAb) medium (Hyclone, Logan, UT). Monoclonal antibody TA99 (mouse IgG2a), directed against the gp75 antigen present on B16F10 melanoma cells, was purified from hybridoma supernatants by protein A-Sepharose chromatography.

MPL. MPL, a derivative of lipid A from Salmonella minnesota, was obtained from Corixa (Seattle, WA).

Melanoma model. Wild-type mice, FcR {gamma}-chain knock-out, Fc{gamma}RI knock-out, or Fc{gamma}RIII knock-out mice, were injected i.v. with 1.5 x 105 B16F10 tumor cells (in 100 µL saline) on day 0. For treatments with an antibody dosage of 200 µg (6), mice were injected i.p. with TA99 antibody (or PBS as control) on days 0, 2, 4, 7, 9, and 11. For combination treatments with suboptimal antibody and MPL concentrations, mice were injected with MPL (0.5 µg in 100 µL PBS) or 100 µL PBS s.c. on days –1, 4, and 8. A suboptimal dose of TA99 antibody (10 µg in 100 µL PBS) or 100 µL PBS (as control) were injected i.p. at days 0, 2, 4, 7, 9, and 11. At day 21, mice were sacrificed, and lungs were scored for numbers of metastases and tumor load. Tumor load was defined as the sum of the following scores: metastases <1 mm were scored as 1; metastases between 1 and 2 mm were scored as 3; and metastases >2 mm were scored as 10, as detailed in ref. (14).

Statistical analyses. ANOVA analyses were done using SPSS software (Chicago, IL). All experiments were done a minimum of two times. Ps < 0.05 were considered significant.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
To dissect the role of individual Fc{gamma}R in antibody therapy of melanoma, we injected wild-type and Fc{gamma}R knock-out mice i.v. with B16F10 tumor cells and studied the effect of antibody treatment. The TA99 antibody, specific for the gp75 tumor antigen, induced a profound protective effect in wild-type mice, which was abrogated in FcR {gamma}-chain–/– mice (Fig. 1). These results confirmed an earlier report, exemplifying the importance of activating Fc{gamma}R in antibody-mediated antitumor effects (6). We then did experiments in Fc{gamma}RI and Fc{gamma}RIII knockout mice. Fc{gamma}RI represents the sole Fc{gamma}R class capable of binding monomeric IgG with high affinity (2) and can potently initiate various immune cell functions, including antibody-dependent, cell-mediated cytotoxicity; antigen uptake; and induction of antigen presentation (12). Fc{gamma}RI–/– mice exhibit various defects, such as an impaired phagocytosis of IgG2a-immune complexes, impaired ADCC, and antigen presentation (12). Fc{gamma}RIII plays a role in anaphylactic and inflammatory responses (13). Antibody TA99 induced a profound antitumor effect in Fc{gamma}RIII knockout mice (Fig. 1). Expression of Fc{gamma}RI proved essential for mAb TA99-mediated effects, as antibody treatment in Fc{gamma}RI–/– mice induced no therapeutic effect (Fig. 1). These data indicated Fc{gamma}RI to be instrumental for the TA99-induced effects.


Figure 1
View larger version (25K):
[in this window]
[in a new window]
  		Figure 1. Fc{gamma}RI is essential for antitumor effects induced by TA99 antibody. Wild-type, FcR {gamma}-chain–/–, Fc{gamma}RI–/–, or Fc{gamma}RIII–/– mice were challenged i.v. with 1.5 x 105 B16F10 tumor cells and injected i.p. with 200 µg mAb TA99 or PBS (control) on days 0, 2, 4, 7, 9, and 11. After 21 days, mice were sacrificed, lungs were excised, and tumor loads were scored as detailed in Materials and Methods. A, lungs of Fc{gamma}RI–/– and Fc{gamma}RIII–/– mice treated with PBS or mAb TA99; black nodules represent metastases. B, tumor load scores in wild-type, FcR {gamma}-chain–/–, Fc{gamma}RI–/–, and Fc{gamma}RIII–/– mice. Tumor loads in PBS-treated mice were set at 100%. Columns, average; bars, SE. Representative for two experiments, each with six mice per group.

 
Choice of antibody isotype can influence binding to Fc{gamma} receptors. Mouse IgG2a antibodies can bind Fc{gamma}RI and Fc{gamma}RIII, albeit with far higher affinity to Fc{gamma}RI (12). However, in the case of the absence of Fc{gamma}RI, the TA99 antibody should still be able to bind to Fc{gamma}RIII, thus not explaining the dramatic effect on antitumor response in Fc{gamma}RI–/– mice. If an antibody of another subclass would be employed (e.g., IgG1), different results might be expected, although this antibody would still be able to bind to Fc{gamma}RI. Very recently, a new class of murine Fc{gamma}R, Fc{gamma}RIV, has been characterized as an IgG2a and IgG2b receptor (3). Because the effect of TA99 antibody was observed to be absent in Fc{gamma}RI–/– mice, Fc{gamma}RIV may play only a minor role, if any, in TA99 antibody-induced effects.

We next evaluated the influence of MPL on TA99-induced antitumor effects. MPL is a TLR-4 agonist, which has similar adjuvant properties as LPS, without inducing toxicity (9). With suboptimal amounts of TA99 or MPL used as monotherapies, mice developed metastases (Fig. 2). Combination of TA99 antibody and MPL, however, consistently led to lower numbers of metastases (Fig. 2). The Fc{gamma}R dependency of TA99 effects in the presence of MPL was analyzed in FcR {gamma}-chain–/– mice. These animals were challenged with tumor cells and injected with antibody or MPL alone or in combination. The protective effect of the combination was abrogated in FcR {gamma}-chain–/– mice (Fig. 3A). We evaluated the contribution of Fc{gamma}RI by challenging Fc{gamma}RI–/– mice with B16F10 tumor cells followed by treatment with antibody, MPL, or antibody plus MPL. Fc{gamma}RI was, again, found essential for induction of a therapeutic effect with the combination therapy (Fig. 3B).


Figure 2
View larger version (26K):
[in this window]
[in a new window]
  		Figure 2. Effect of MPL on therapeutic efficacy of TA99 antibody. Wild-type mice were challenged i.v. with tumor cells and treated with PBS, a suboptimal dose of mAb TA99 (10 µg), a suboptimal dose of MPL (0.5 µg), or with TA99 plus MPL. After 21 days, mice were sacrificed, lungs were excised, and tumor loads scored as detailed in Materials and Methods. A, lungs of wild-type mice; black nodules represent metastases. B, tumor loads scored in wild-type mice. Representative for two experiments, each with six mice per group.

 

Figure 3
View larger version (11K):
[in this window]
[in a new window]
  		Figure 3. Fc{gamma}RI is essential for combination therapy. FcR {gamma}-chain–/– (A) or Fc{gamma}RI–/– mice (B) were challenged i.v. with tumor cells and treated with PBS, a suboptimal dose of mAb TA99 (10 µg), a suboptimal dose of MPL (0.5 µg), or with TA99 combined with MPL. After 21 days, mice were sacrificed, lungs were excised, and tumor loads scored. Representative for two experiments, each with six mice per group.

 
MPL is known to activate macrophages and dendritic cells, and adjuvant studies in vivo documented MPL to induce antigen-specific CTL and to skew T-helper balance toward a Th1 phenotype (11, 15). MPL improve the capacity of B cells and macrophages to prime T and B cells and induce the maturation of splenic dendritic cells in situ. Furthermore, MPL triggers cytokine production, which can have an effect on the development of both humoral and cellular immune responses (16), indicating MPL to be a suitable candidate adjuvant for antibody therapy.

The effector cells, which can be involved in antibody-mediated antitumor effects, are natural killer (NK) cells, polymorphonuclear (PMN), monocytes, and macrophages. Earlier studies examining effector cells in the B16 model during antibody treatment excluded a role for NK cells and B and T cells (17). In these studies, microscopic analyses of lung tissues documented abundant infiltration of macrophages (5), supporting a role for macrophages during antibody therapy. Murine Fc{gamma}RI is expressed on monocytes, macrophages, and dendritic cells but not on PMN (12). As we observed Fc{gamma}RI to be central for antibody-mediated antitumor effects, we hypothesize Fc{gamma}RI-expressing monocytes/macrophages to be of importance for the TA99-induced antitumor effects and not NK cells or PMN. We are currently performing studies (e.g., monocytes/macrophage depletion with use of clodronate liposomes) to further address the role of the effector cells involved in this model.

The importance of human Fc{gamma} receptors for tumor therapy has been documented, where Fc{gamma}R polymorphisms were shown to affect the outcome of antibody treatments in cancer patients (18–20). A better understanding of the role of individual Fc{gamma}R in antibody therapies is important to further optimize antibody therapeutic approaches in man.


   Acknowledgments
 
Grant support: Dutch Cancer Society "K.W.F." grant UU 2001-2496.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Anja van der Sar, Toon Hesp, Wendy Kaspers, Sabine Versteeg, Agnes Goderie, and Gerard Geelen for excellent animal care; Esther Rudolph and Patrick Luijk for help with digital photography; and Soeniel Jhakrie, Edwin van Voskuilen, Marcel Brandhorst, and Judy Bos-de Ruijter for culturing and purification of TA99 antibody.


   Footnotes
 
Note: J.G.J. van de Winkel and J.H.W. Leusen contributed equally to this work.

Received 8/11/05. Revised 10/18/05. Accepted 12/21/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292–302.[CrossRef][Medline]
  2. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275–90.[CrossRef][Medline]
  3. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005;23:41–51.[CrossRef][Medline]
  4. Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN. Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol 1988;90:459–66.[CrossRef][Medline]
  5. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609–14.[Abstract/Free Full Text]
  6. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652–6.[Abstract/Free Full Text]
  7. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994;76:519–29.[CrossRef][Medline]
  8. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004;4:512–20.[CrossRef][Medline]
  9. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6:495–524.[Medline]
  10. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498–505.[CrossRef][Medline]
  11. Wijburg OL, van den Dobbelsteen GP, Vadolas J, Sanders A, Strugnell RA, van Rooijen N. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur J Immunol 1998;28:479–87.[CrossRef][Medline]
  12. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, et al. Fc{gamma}RI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002;16:391–402.[CrossRef][Medline]
  13. Hazenbos WL, Gessner JE, Hofhuis FM, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc{gamma}RIII (CD16) deficient mice. Immunity 1996;5:181–8.[CrossRef][Medline]
  14. van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003;101:253–8.[Abstract/Free Full Text]
  15. De Becker G, Moulin V, Pajak B, et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000;12:807–15.[Abstract/Free Full Text]
  16. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003;2:219–29.[CrossRef][Medline]
  17. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 1996;2:1837–42.[Abstract]
  18. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc{gamma}RIIIa gene. Blood 2002;99:754–8.[Abstract/Free Full Text]
  19. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940–7.[Abstract/Free Full Text]
  20. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004;22:4665–72.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Virol.Home page
L. G. Perez, M. R. Costa, C. A. Todd, B. F. Haynes, and D. C. Montefiori
Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41
J. Virol., August 1, 2009; 83(15): 7397 - 7410.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. M. Saenger, Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok
Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma
Cancer Res., December 1, 2008; 68(23): 9884 - 9891.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. V. Beum, D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes
J. Immunol., December 1, 2008; 181(11): 8120 - 8132.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Otten, G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. J. Beelen, J. G. J. van de Winkel, and M. van Egmond
Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc{gamma}RI and Fc{gamma}RIV
J. Immunol., November 15, 2008; 181(10): 6829 - 6836.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Boross, P. L. van Lent, J. Martin-Ramirez, J. van der Kaa, M. H. C. M. Mulder, J. W. C. Claassens, W. B. van den Berg, V. L. Arandhara, and J. S. Verbeek
Destructive Arthritis in the Absence of Both Fc{gamma}RI and Fc{gamma}RIII
J. Immunol., April 1, 2008; 180(7): 5083 - 5091.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Baudino, F. Nimmerjahn, S. Azeredo da Silveira, E. Martinez-Soria, T. Saito, M. Carroll, J. V. Ravetch, J. S. Verbeek, and S. Izui
Differential Contribution of Three Activating IgG Fc Receptors (Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV) to IgG2a- and IgG2b-Induced Autoimmune Hemolytic Anemia in Mice
J. Immunol., February 1, 2008; 180(3): 1948 - 1953.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. W. Ding, T. Zhou, H. Zeng, L. Ma, J. S. Verbeek, D. Yin, J. Shen, and A. S. Chong
Hyperacute Rejection by Anti-Gal IgG1, IgG2a, and IgG2b Is Dependent on Complement and Fc-{gamma} Receptors
J. Immunol., January 1, 2008; 180(1): 261 - 268.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. E. Strome, E. A. Sausville, and D. Mann
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Oncologist, September 1, 2007; 12(9): 1084 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. M. Sharkey and D. M. Goldenberg
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Brodzik, M. Glogowska, K. Bandurska, M. Okulicz, D. Deka, K. Ko, J. van der Linden, J. H. W. Leusen, N. Pogrebnyak, M. Golovkin, et al.
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells
PNAS, June 6, 2006; 103(23): 8804 - 8809.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bevaart, L.
Right arrow Articles by Leusen, J. H.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bevaart, L.
Right arrow Articles by Leusen, J. H.W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online